As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our peer review process during normal times. Please do let us know if you need additional time. Our systems will continue to remind you of the original timelines but we intend to be highly flexible at this time.
COVID-19 and impact on peer review
Clinical Sarcoma Research accepted for inclusion in SCIE
We are delighted to announce that Clinical Sarcoma Research has been accepted for inclusion in Science Citation Index Expanded (SCIE), a key database of Web of Science, published by Clarivate Analytics. Starting 2020, Clinical Sarcoma Research will be published in the annual Journal Citation Reports, at which point it will receive the associated journal metrics, such as Immediacy Index, Eigenfactor Score, and Journal Impact Factor.
Thematic series: The challenges of sarcoma
This thematic series explores the challenges clinicians face in early recognition and diagnosis of sarcomas. We're delighted to produce the series comprising of two review articles written by leading global experts in the field, in collaboration with Springer Healthcare IME.
Aims and scope
The journal is an integral part of the euroSARC project funded by the European Commission through the 7th Framework Programme under Grant Agreement no. 278742.
Soft tissue sarcoma webcast
Chair: Robin Jones (The Royal Marsden Hospital, London, UK)
Bernd Kasper (University Medical Centre Mannheim, Mannheim, Germany)
Vasilios Karavasilis (University College London Hospital, London, UK)
This webcast provides the latest information on the current and emerging treatment formats which could improve outcomes for patients with STS, the standards of care for patients with STS and how these are best met within the context of a multidisciplinary team.
Click here to go to the webcast page
After viewing the webcast, Soft tissue sarcoma: what is best practice? You should be able to:
- Assess the new treatment and diagnosis paradigms for A-STS and explain how to best apply them to their daily practice.
- Explain the current best practice for providing treatment STS within the context of the multidisciplinary team.
Meet the Editors-in-Chief
Dr. Paolo G. Casali is head of the Adult Mesenchymal Tumour Medical Oncology Unit, Istituto Nazionale Tumori, Milan, Italy. He serves as Secretary of the Ethics Committee of his institution. His research focuses on rare tumors, especially adult sarcomas, including gastrointestinal stromal tumors (GIST), and uncommon histological types. He is the Secretary of the Italian Sarcoma Group, and is a member of the EORTC Soft Tissue & Bone Sarcoma Group. He chairs the Italian Network on Rare Tumors, a collaborative effort among Italian cancer centers, which endeavours to exploit distant patient sharing in order to improve quality of care and diminish health migration for rare solid cancers. He acts as an Editor of START, an Italian-based, European state-of-the-art instrument on cancer treatment. He is a member of the Executive Board of ESMO as chair of the Public Policy/European Affairs Committee, and is Faculty Coordinator for Sarcoma. He is a member of the Policy Committee of ECCO. He teaches Medical Therapy of Rare Cancers at the Milan University postgraduate school in Oncology.
Dr. Angelo Paolo Dei Tos is the Director of the Department of Oncology and Director of Anatomic Pathology at the General Hospital in Treviso, Italy, and Contract Professor of Pathology at the University of Padua School of Medicine. He is the Chairman of the Pathology Subcommittee of the Soft Tissue and Bone Group of EORTC, Founder and Past Chairman of the Working Group on Soft Tissue Tumor Pathology of the European Society of Pathology, Past President of the International Society of Bone and Soft Tissue Pathology, panel member for the WHO classification of Bone and Soft Tissue Sarcomas, member of the Board of Directors of the Connective Tissue Oncologic Society, and a faculty member of ESMO. He has authored or co-authored more than 140 peer reviewed scientific papers.
Annual Journal Metrics
71 days to first decision for reviewed manuscripts only
69 days to first decision for all manuscripts
144 days from submission to first decision
15 days from acceptance to publication
93 Altmetric Mentions